Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: Evidence from French health data

Annals of Pharmacotherapy

Volumn 45, Issue 2, 2011, Pages 179-188

  Mease, Philip J ^a   Zimetbaum, Peter J ^b   Duh, Mei Sheng ^c   Vekeman, Francis ^d   Guérin, Annie ^d   Boerstoel Streefland, Mariette ^e   Jiang, Wenjun ^f   Lefebvre, Patrick ^d  

^a Seattle Rhumatology Associates   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c ANALYSIS GROUP   (United States)

^d GROUPE D ANALYSE   (Canada)

^e FOREST RESEARCH INSTITUTE   (United States)

^f Pharmacovigilance and Risk Management   (United States)

Author keywords

Amitriptyline; Cardiovascular event; Milnacipran; Venlafaxine

Indexed keywords

AMITRIPTYLINE; MILNACIPRAN; VENLAFAXINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DATA BASE; DEPRESSION; ELECTRONIC MEDICAL RECORD; FEMALE; FIBROMYALGIA; HEALTH SURVEY; HEART ARREST; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STROKE; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; HEART FAILURE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK; UNITED STATES;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; CYCLOPROPANES; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK; SEROTONIN UPTAKE INHIBITORS; STROKE; UNITED STATES; VENLAFAXINE HYDROCHLORIDE;

EID: 79951885194     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P391     Document Type: Article

References (25)

1. Leo RJ, Brooks VL. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs 2006;7:637-42. (Pubitemid 44018347)
2. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55:320-2. (Pubitemid 38117171)
3. Stahl SM. Essential psychopharmacology: the prescriber's guide. New York, NY: Cambridge University Press, 2007.
4. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:1305-22. (Pubitemid 28016506)
5. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-58. (Pubitemid 28022649)
6. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995;10(suppl 2):15-20.
7. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16:54S-9S; discussion 9S-61S.
8. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995;56:574-9. (Pubitemid 26002163)
9. Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007;23:175-84. (Pubitemid 46191681)
10. Wernicke J, Lledo A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007;30:437-55. (Pubitemid 46740340)
11. Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12:99-108. (Pubitemid 27286559)
12. Gendreau J, Palmer RH, Thacker K. Milnacipran is safe and well tolerated in the treatment of fibromyalgia. Presented at: 27th Annual Scientific Meeting of the American Pain Society, Tampa, FL, May 8-10, 2008.
13. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial [correction appears in J Rheumatol 2009;36: 661]. J Rheumatol 2009;36:398-409.
14. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial [correction appears in Clin Ther 2009;31:446]. Clin Ther 2008;30:1988-2004.
15. Marshall JB, Forker AD. Cardiovascular effects of tricyclic antidepressant drugs: therapeutic usage, overdose, and management of complications. Am Heart J 1982;103:401-14. (Pubitemid 12178725)
16. Glassman AH. Cardiovascular effects of tricyclic antidepressants. Annu Rev Med 1984;35:503-11.
17. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-85. (Pubitemid 41429029)
18. Ansseau M, Von Frenckell R, Papart P, et al. Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depressive inpatients. Hum Psychopharmacol 1989;4:221-7.
19. Leinonen E, Lepola U, Koponen H, Mehtonen OP, Rimon R. Long-term efficacy and safety of milnacipran compared with clomipramine in patients with major depression. Acta Psychiatr Scand 1997;96:497-504. (Pubitemid 27519795)
20. Tignol J, Pujol-Domenech J, Chartres JP, et al. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatr Scand 1998;97:157-65. (Pubitemid 28145463)
21. Guelfi JD, Ansseau M, Corruble E, et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol 1998;13:12 1-8.
22. Clerc G. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 2001;16:145-51. (Pubitemid 32402359)
23. Lopez-Ibor JJ, Conesa A. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder. Curr Med Res Opin 2004;20:855-60. (Pubitemid 38821523)
24. Lee MS, Ham BJ, Kee BS, et al. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Curr Med Res Opin 2005;21:1369-75. (Pubitemid 41368568)
25. Ferdinand KC. Hypertension in minority populations. J Clin Hypertens (Greenwich) 2006;8:365-8.